Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
195
-
Total 13F shares, excl. options
-
118M
-
Shares change
-
+14.7M
-
Total reported value, excl. options
-
$1.62B
-
Value change
-
+$193M
-
Put/Call ratio
-
0.58
-
Number of buys
-
93
-
Number of sells
-
-80
-
Price
-
$13.85
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2021
244 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2021.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 195 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 118M shares
of 210M outstanding shares and own 56.21% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.8M shares), BAKER BROS. ADVISORS LP (12.7M shares), VANGUARD GROUP INC (9.41M shares), STATE STREET CORP (8.25M shares), PICTET ASSET MANAGEMENT SA (5.06M shares), Fisher Asset Management, LLC (4.1M shares), Sarissa Capital Management LP (4.04M shares), FMR LLC (3.9M shares), RP Management, LLC (3.85M shares), and GEODE CAPITAL MANAGEMENT, LLC (3.22M shares).
This table shows the top 195 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.